In modern healthcare, biomarkers are an integral part of approaches to monitoring patient health and condition, providing researchers with a means of predicting treatment response. But what was the first biomarker to be discovered?

The high sensitivity and specificity of ddPCR assays makes the approach well-suited for screening diseases and diagnosing cancer subtypes. Here, we explore some of the ways in which medical researchers are using the technology to pioneer detection of circulating biomarkers for liquid biopsies.

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction.

The applications and opportunities offered by digital polymerase chain reaction (dPCR) technology have provided new techniques for molecular diagnostics. With an estimated global market value of USD $1bn by 2032, the future looks promising for dPCR approaches.

On-Demand Webinar featuring Dr Mo Jain, Founder & CEO of Sapient

This webinar shares how next-generation, high throughput mass spectrometry, advanced data analysis, and population-scale data are being leveraged for robust discovery of biomarkers that can be used to align patients, disease biology, and therapeutic interventions for clinical trials.

Precision medicine involves tailoring a therapeutic to a patient’s disease: developing precision therapies require an accurate identification of therapeutic targets from available data.

Research from the University of Pennsylvania suggests that stress levels may have a profound impact on the efficacy of treatment approaches for bowel disease.

Amongst the hundreds of avenues of scientific discovery being pioneered today, one of the most compelling by far is that of artificial life. Synthetic biology forms a major branch of this.